IRVINE, CA--(Marketwire - January 12, 2011) - Edwards Lifesciences Corporation (NYSE: EW), the global leader in the science of heart valves and hemodynamic monitoring, today announced the appointment of Aimee S. Weisner as corporate vice president, general counsel. Weisner will lead the company’s legal organization and will report to Edwards’ chairman and CEO, Michael A. Mussallem. Bruce P. Garren, who has been the company’s general counsel since 2000, will assume a new role as corporate vice president, public affairs and special counsel. Garren will continue to lead government affairs and global reimbursement, and will now also be responsible for global communications, medical affairs and specific legal matters.
“We welcome Aimee to this important role on our executive leadership team,” said Mussallem. “Her extensive legal experience in all aspects of the medical technology industry complements our team well and we look forward to her contributions.”
Weisner was previously the executive vice president, administration and secretary at Advanced Medical Optics, Inc. (AMO) where she was responsible for legal, human resources, compliance and internal audit, and previously served as general counsel. Prior to joining AMO, she served as vice president, assistant general counsel and assistant secretary at Allergan. Weisner also previously practiced in the corporate and securities group at the law firm of O’Melveny & Myers LLP. She received her juris doctor degree from Loyola Law School in Los Angeles and her bachelor’s degree in communications from California State University, Fullerton.
About Edwards Lifesciences
Edwards Lifesciences is the global leader in the science of heart valves and hemodynamic monitoring. Driven by a passion to help patients, the company partners with clinicians to develop innovative technologies in the areas of structural heart disease and critical care monitoring that enable them to save and enhance lives. Additional company information can be found at www.edwards.com.
Edwards, Edwards Lifesciences and the stylized E logo are trademarks of Edwards Lifesciences Corporation.
Investor Contact:
David K. Erickson
949-250-6826
Media Contact:
Amanda C. Fowler
949-250-5070